This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
See Cramer's multi-million dollar portfolio for FREE and get his new book Get Rich Carefully! Learn More

Biotech

Earnings Countdown: Intel, Yahoo!, CSX, Abbott Labs

Earnings Countdown: Intel, Yahoo!, CSX, Abbott Labs

CSX Corp and Abbott Labs complete the four companies that report after the close today or before the opening bell on Wednesday.

04/15/14 - 08:47 AM EDT

The Recent Performance of 'Baker Brother Biotech Stocks' is Awful

Healthcare's most closely followed hedge fund is losing money during the biotech bubble burst.

04/15/14 - 12:23 PM EDT

Bubble Bursting? Only for Biotech & Internet Stocks

Bubble Bursting? Only for Biotech & Internet Stocks

The recent sluggish performance of U.S. stocks is leading some market watchers to question whether we're witnessing the bursting of an equity bubble.

04/15/14 - 11:48 AM EDT

Article
Johnson & Johnson Beats Earnings and Will Lift Dow, Biotech: StockTwits

Johnson & Johnson Beats Earnings and Will Lift Dow, Biotech: StockTwits

Investors say Johnson & Johnson's earnings beat will take the Dow and the biotech sector higher today.

04/15/14 - 11:04 AM EDT

Article
Capitulation? Or a Bounce to Sell Into Now?

Capitulation? Or a Bounce to Sell Into Now?

Prepare yourself for more downside even if we do bounce this week.

04/14/14 - 11:37 AM EDT

Video
Stocks Open Higher on Citi Surprise, Surging Retail Sales Stocks Open Higher on Citi Surprise, Surging Retail Sales
  • Tickers in this article:
  • C
  • GSK

Stocks opened higher open on Monday, buoyed by better-than-expected earnings from Citigroup, while retail sales jumped 1.1% in March, surpassing economists' expectations.

04/14/14 - 09:53 AM EDT

Article
FDA Approves Novartis' ALK Inhibitor! Maybe...Really Soon?

FDA Approves Novartis' ALK Inhibitor! Maybe...Really Soon?

Someone at Novartis screwed up today by sending out a mass email announcing the FDA approval of a new lung cancer drug ceritinib. Brand name: Zykadia. The only problem is FDA hasn't announced the approval of Zykadia yet.

04/11/14 - 03:07 PM EDT

Article
Oh Biotech, You Are a Cruel Bitch

Oh Biotech, You Are a Cruel Bitch

Wednesday's mini rally was a head fake, leading to more selling Thursday.

04/10/14 - 01:09 PM EDT

Video
Markets Jump on Fed Minutes, Loose Policy Stance Reiterated Markets Jump on Fed Minutes, Loose Policy Stance Reiterated
  • Tickers in this article:
  • DJI
  • IXIC

Biotech and social media stocks continued their rebound after selling off earlier this year, while earnings season was off to a promising start after strong results from bellwether stock Alcoa.

04/09/14 - 04:22 PM EDT

Article
When is a Warrant Not a Warrant? When Northwest Bio is Raising Money.

When is a Warrant Not a Warrant? When Northwest Bio is Raising Money.

  • Tickers in this article:
  • NWBO

An explanation of Northwest Bio's "up to" $32 million financing deal.

04/10/14 - 10:24 AM EDT

Article
Conatus Pharma Deserves a Look by Investors in Love With Liver Disease Stocks

Conatus Pharma Deserves a Look by Investors in Love With Liver Disease Stocks

Conatus Pharmaceuticals is an early-stage developer of drugs to treat diseases of the liver with a favorable risk-reward profile, particularly after recent investor selling in the biotech sector has created some nice values.

04/09/14 - 10:06 AM EDT

Article
April 9 Premarket Briefing: 10 Things You Should Know

April 9 Premarket Briefing: 10 Things You Should Know

U.S. stock futures rise ahead of the minutes of the latest Fed meeting; Toyota to recall 6.4 million vehicles; NHTSA fines GM $7,000 a day; Alcoa's adjusted earnings top forecasts.

04/09/14 - 08:10 AM EDT

Article
Why Spectranetics (SPNC) Stock Is Plummeting Today

Why Spectranetics (SPNC) Stock Is Plummeting Today

  • Tickers in this article:
  • SPNC

Spectranetics (SPNC) shares are down -11.6% to $23.08 in trading on Tuesday.

04/08/14 - 02:05 PM EDT

Article
IsoRay (ISR) Trips After Strong Monday Run

IsoRay (ISR) Trips After Strong Monday Run

  • Tickers in this article:
  • ISR

IsoRay (ISR) is slipping after a strong run-up on Monday on positive trial news.

04/08/14 - 01:54 PM EDT

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
DOW 16,262.56 +89.32 0.55%
S&P 500 1,842.98 +12.37 0.68%
NASDAQ 4,034.1610 +11.4670 0.29%

Brokerage Partners

Advertising Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs